Kirkeby Cell Therapy APS Financials, key figures and credit report
Gross profit 25.9 kDKK FY 2025 -56.5% vs 2024
EBIT 25.9 kDKK FY 2025 -56.5% vs 2024
Net debt -1 518.4 kDKK FY 2025 +9.2% vs 2024
Quick ratio 88.0 FY 2025 +14.4 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 246.59 | 107.77 | 287.23 | 59.52 | 25.87 |
| EBIT | 246.59 | 107.77 | 287.23 | 59.52 | 25.87 |
| Other financial income | 116.75 | 62.16 | 14.52 | 83.50 | 0.68 |
| Other financial expenses | -2.45 | -5.79 | -1.13 | -3.08 | -46.06 |
| Pre-tax profit | 360.89 | 164.14 | 300.63 | 139.94 | -19.50 |
| Income taxes | -79.64 | -36.52 | -66.37 | -28.78 | |
| Net earnings | 281.25 | 127.62 | 234.25 | 111.16 | -19.50 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible rights | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible assets total | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 206.39 | 146.47 | 24.41 | ||
| Current other receivables | 10.34 | 32.28 | 22.81 | 9.46 | |
| Current deferred tax assets | 30.00 | ||||
| Short term receivables total | 216.72 | 146.47 | 32.28 | 47.22 | 39.45 |
| Other current investments | 1 248.87 | 1 413.85 | 1 428.37 | 1 511.87 | 613.75 |
| Cash and bank deposits | 177.94 | 122.30 | 295.59 | 160.14 | 905.86 |
| Cash and cash equivalents | 1 426.81 | 1 536.15 | 1 723.96 | 1 672.01 | 1 519.61 |
| Balance sheet total (assets) | 1 643.53 | 1 682.63 | 1 756.24 | 1 719.23 | 1 559.07 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 |
| Shares repurchased | 114.40 | 117.80 | 122.00 | 135.00 | 158.80 |
| Retained earnings | 1 141.37 | 1 304.82 | 1 310.45 | 1 409.70 | 1 362.06 |
| Profit of the financial year | 281.25 | 127.62 | 234.25 | 111.16 | -19.50 |
| Shareholders equity total | 1 577.02 | 1 590.24 | 1 706.70 | 1 695.85 | 1 541.35 |
| Non-current liabilities total | |||||
| Current trade creditors | 7.50 | 16.50 | 16.50 | 16.50 | 16.50 |
| Current owed to participating | 1.22 | ||||
| Short-term deferred tax liabilities | 19.64 | 12.52 | 31.82 | 0.78 | |
| Other non-interest bearing current liabilities | 39.37 | 63.36 | 1.22 | 6.10 | |
| Current liabilities total | 66.51 | 92.38 | 49.54 | 23.38 | 17.72 |
| Balance sheet total (liabilities) | 1 643.53 | 1 682.63 | 1 756.24 | 1 719.23 | 1 559.07 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated